 |
 |
---------- From: Leo Fuhr <[log in to unmask]> To: [log in to unmask] Subject: PERMAX as monotherapy in early PD; my particular response to this trial Date: Saturday, August 14, 1999 9:50 PM The last part of July 1999 I posted to PIE about my neuro asking that I try monotherapy w/PERMAX(Pergolide) since I'm 48(49 in sept) and he hoped to delay using levodopa and it's long term side effects. Many of you wrote and commented on using PERMAX alone, the amount of PERMAX being taken and Brian Collins and others mentioned that w/o levodopa, they weren't sure I could get sufficient relief from pd symptoms. I called my neuro's office on 8/6/99 and told of my increasing pd symptoms and the nausea/diarreha I was having as side effects of PERMAX. I asked if I could reintroduce SINEMETCR in low dosage to give me relief until I could get in for my 8/18/99 appointment. My neuro was paged, called back immediately and the nurse called me and said I could reintroduce SINEMETCR 50/200 at 1/2 tab a day and could gradually add more if needed but to try to keep dose low and continue the PERMAX .25 mg tab @ 3x a day. I immediately took the 1/2 tab w/orange juice and within 1/2 hour felt better. I just wanted to thank all the PIE responders to my message. You gave me the courage to say what I really felt....w/o levodopa the rigidity, left shldr pain, and all the symptoms that baffled my primary care dr and had him referring me to a neuro for proper dx were returning. I also kept a drug diary w/comments that helped me remember how/when I felt certain way. Today I rec'd NPF Parkinson's Report Vol XX No. 2 Summer 1999 that has featured on the cover the article:"Pergolide in the Treatment of PD". The article can also be found at <http://www.parkinson.org/pergolide.htm> The article explains that in one study, 48% of newly dx with PD patients showed marked or moderate improvement & 32% mild improvement. I understand why my mds hoped I'd be in the 48% group. I'm glad he understood when i called to complain that results in my own body were not successful. Another example of the uniqueness of this disease and how drugs may differ for each patient. Jeanette Fuhr 48/47/44?